Pharmacological properties

Pharmacodynamics. the inzhest of an oksa — a synthetic analog of hormone of a yellow body. medicine causes transformation of a mucous membrane of a uterus from a proliferation phase in a secretory phase that is necessary for normal implantation, and after fertilization promotes its transition to the state demanded for oospore development. the inzhest of an oksa also reduces excitability and contractility of muscles of a uterus and uterine tubes that provides pregnancy preservation; stimulates development of trailer elements of mammary glands. stimulates in low doses, and in high — suppresses secretion of gonadotropic hormones. slows down action of Aldosteronum that leads to strengthening of secretion of sodium and chlorine with urine. possesses catabolic and immunodepressive effect.

more resistant in an organism, than progesterone, works more slowly and renders the prolonged gestagenny effect. After a single injection in oil Inzhesta Oksi his action lasts from 8 to 14 days.

Pharmacokinetics. After an injection in oil it is slowly absorbed in the injection site. Therapeutic concentration remains within 7–14 days.

Indication

Pathological processes caused by insufficiency of a yellow body: threat of an abortion; primary and secondary amenorrhea; polymenorrhea; dysfunctional uterine bleedings; hyperplastic processes in endometrium, endometriosis.

Use

is Applied at adult women. the medicament is administered by in oil. for the purpose of prevention and treatment of threat of an abortion enter 125–250 mg (1–2 ml of 12.5% of solution) once a week. to an inzhest of an oksa apply a pregnancy trimester only in i.

At an amenorrhea (primary and secondary) is appointed directly after the termination of intake of estrogenic medicines. Enter 250 mg of Inzhesta Oksi once or in two steps.

for the purpose of normalization of a menstrual cycle (at a polymenorrhea, dysfunctional uterine bleedings) to Inzhest Oksi enter in a dose 62.5-125 mg (0.5-1 ml of 12.5% of solution) for the 20-22nd day of a cycle.

At women with an endometrium hyperplasia (in the absence of hormonal active tumors of ovaries) aged up to 45 years in the I phase of a menstrual cycle are appointed by estrogen (ethinylestradiol of 0.05 mg/days from the 5th to the 25th day of a cycle) and to Inzhest Oksi on 1 ml of 12.5% of solution once a week to the 5th, 12th and 19th day of a cycle during 4–5 cycles. To women 45 years are aged more senior enter only Inzhesta Oksi on 2 ml of 12.5% of solution during 6–8 menstrual cycles once a week.

Contraindication

Hypersensitivity to medicine components; an abnormal liver function, liver diseases (hepatitis, cirrhosis), a benign hyperbilirubinemia, cholestatic jaundice during pregnancy or in the anamnesis; renal failure; malignant tumors of a mammary gland and genitals; an extrauterine pregnancy or the stood pregnancy in the anamnesis, vaginal bleedings of unspecified genesis, a state after abortion; nervous breakdowns with the depression phenomena, tachycardia; a venous or arterial thrombembolia, heavy thrombophlebitis or these states in the anamnesis; porphyria.

Side effects

from an endocrine system: increase in body weight, pain and nagrubaniye of mammary glands, violations of a menstrual cycle, irregular uterine bleedings, amenorrhea, oligomenorrhea, symptoms of a premenstrual syndrome, hirsutism, decrease in a libido;

from genitals: spasms of a uterus, violation from external genitals, such as burning, dryness, genital itch, vaginal discharges, vaginal mycosis;

from nervous system: dizziness, headache, depression, increased fatigue, insomnia, drowsiness, paresthesias;

from a cardiovascular system: increase in the ABP, tachycardia, short wind, blood circulation violation, venous thrombembolia;

from digestive system: changes of appetite, nausea, vomiting, abdominal distension, abdominal pain, lock, diarrhea, abnormal liver function and changes of functional trials of a liver, cholestatic jaundice;

from a metabolism: hypostases, an albuminuria, violation of tolerance to glucose, a delay of liquid, change of a lipidic profile of blood plasma;

from the immune system: anaphylactic reactions, reactions of hypersensitivity;

from skin and hypodermic fabric: the alopecia, an acne, a yellow nevus pigmentosus on a face (hloazm), are possible allergic reactions on skin — rashes, an itch, urticaria, a multiformny erythema, a Quincke's disease;

from an organ of sight: disorder of vision, retina thrombosis, inflammation of optic nerves;

in the injection site: changes in the injection site, including pain and a swelling;

general violations: fever.

Excess amount of progesterone can cause virilescence of a female fruit (to uncertainty of sex).

Special instructions

With care should use medicament at patients with ag, cardiovascular diseases, diabetes, oh, of epilepsy, migraine.

With care at patients with other diseases promoting a liquid delay at patients with mental violations in the anamnesis, medicine needs to be cancelled at emergence of the first symptoms of a depression.

At patients with diabetes needs to control carefully glucose indicators in blood. It is not necessary to use medicament at bleedings from a genital tract which reason is not established, and to patients in whose anamnesis diseases of peripheral arteries are noted. At use of medicine it is necessary to be attentive to precursory symptoms and symptoms of a thrombembolia, and in case of their emergence the therapy by medicine is required to be stopped.

during treatment recommends carrying out regular surveys which frequency and volume are defined individually.

in the presence of any progestagenzavisimy tumor, for example meningiomas during pregnancy or the previous hormonal therapy of the patient have to be in the anamnesis and/or its progressing under careful observation of the doctor.

.

Use during pregnancy and feeding by a breast. Inzhesta Oksi is applied only in the I trimester of pregnancy at threat of an abortion. The risk of congenital anomalies, including sexual anomalies at children of both sexes, connected with effect of exogenous progesterone during pregnancy, completely is not established.

during feeding by a breast use of medicine is not recommended.

Children. There is no experience of use of medicine for children therefore it cannot be applied in pediatric practice.

Ability to influence speed of response at control of vehicles or work with other mechanisms. Inzhesta Oksi can cause disorders of vision and increased fatigue therefore it is necessary to abstain from control of vehicles and work with other mechanisms.

Interaction

an oksa is reduced by effect of the medicines stimulating myometrium reduction (oxytocin and other means stimulating a tone and sokratitelny activity of myometrium), anabolic steroids (Nandrolonum, metandiyenon), gonadotropic hormones of a hypophysis. in interaction with oxytocin the expressiveness of lactogenic effect decreases. strengthens effect of diuretics, hypotensive medicines, immunodepressants, Bromocriptinum and system coagulants. reduces efficiency of anticoagulants. changes effects of gipoglikemiziruyushchy means. the gestagenny activity is reduced by inductors of microsomal oxidation (carbamazepine, griseofulvin, barbiturates, hydantoin, rifampicin). the combined application of β-adrenomimetik and hydroxyprogesterone of caproate for prevention of premature births promotes reduction of severity of side effects of β-adrenomimetik.

caproate oppresses cyclosporine metabolism, leading to increase in concentration of cyclosporine in blood plasma and to risk of emergence of toxic effects.

Overdose

At use of medicine in doses, above recommended, more often the side effects described in appropriate section arise. at emergence of gestagenzavisimy side effects the treatment needs to be stopped, and after their disappearance — to continue in low doses. in case of need carry out symptomatic treatment.

Storage conditions

In original packing at a temperature not above 25 °C.